Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …
vaccination was implemented. We did a systematic review and meta-analysis of the …
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
C Simoens, PPL Martin‐Hirsch - Cochrane database of …, 2018 - cochranelibrary.com
Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
Human papillomavirus vaccination and cervical cancer risk
L Rahangdale, C Mungo, S O'Connor, CJ Chibwesha… - Bmj, 2022 - bmj.com
Persistent human papillomavirus infection is the central cause of cervical cancer, the leading
cause of cancer death among women worldwide. Clear evidence from both randomized …
cause of cancer death among women worldwide. Clear evidence from both randomized …
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional …
K Kavanagh, KG Pollock, K Cuschieri… - The Lancet infectious …, 2017 - thelancet.com
Summary Background On Sept 1, 2008, Scotland launched routine vaccination for human
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …
HPV vaccination crisis in Japan
SJB Hanley, E Yoshioka, Y Ito, R Kishi - The Lancet, 2015 - thelancet.com
Free vaccination against the human papillomavirus (HPV) began in December, 2010, for
Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the …
Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the …
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study
T Palmer, L Wallace, KG Pollock, K Cuschieri… - bmj, 2019 - bmj.com
Objective To quantify the effect on cervical disease at age 20 years of immunisation with
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …
Cervical cancer incidence in young US females after human papillomavirus vaccine introduction
F Guo, LE Cofie, AB Berenson - American journal of preventive medicine, 2018 - Elsevier
Introduction Since 2006, human papillomavirus vaccine has been recommended for young
females in the US This study aimed to compare cervical cancer incidence among young …
females in the US This study aimed to compare cervical cancer incidence among young …
Present status of human papillomavirus vaccine development and implementation
R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)
This paper summarises the position of ESGO and EFC on cervical screening based on
existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as …
existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as …